A TP53 mutation occurs in ~13% of AML cases (15), and this mutation is an independent prognosis factor for a lower response rate, inferior complete remission duration, and overall survival in chronic lymphocytic leukemia (CLL) (16), AML (17), myelodysplastic syndromes (18), and an ultra-high-risk group of relapsed pediatric T-cell acute lymphoblastic leukemia (TALL) patients (19). The gene discussed is TP53; the disease is T-cell acute lymphoblastic leukemia.